<DOC>
	<DOCNO>NCT00647426</DOCNO>
	<brief_summary>This open-label , single institution , phase II study Sorafenib combination docetaxel carboplatin patient advance non-small cell lung cancer . Docetaxel carboplatin give day 1 every three week cycle . Patients take Sorafenib twice day 1st day treatment continue take medication every day progression disease , prohibitive toxicity , patient withdrawal study . Chemotherapy course repeat every 21 day absence disease progression unacceptable toxicity total four cycle .</brief_summary>
	<brief_title>Phase II Study Sorafenib + Carboplatin Docetaxel First Line Treatment Stage IIIB/IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC clinical radiological evidence advance disease ( Stage IIIB/IV ) Unidimensionally measurable disease Age = &gt; 18 year ECOG performance status 01 Life expectancy &gt; 3 month Smallcell mixed histology include small cell component Prior chemotherapy , biotherapy , radiotherapy area measurable disease Patients peripheral neuropathy grade = &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Stage IIIB/IV</keyword>
</DOC>